HRP20120479T1 - Farmaceutski sastavi sa droksidopom - Google Patents
Farmaceutski sastavi sa droksidopom Download PDFInfo
- Publication number
- HRP20120479T1 HRP20120479T1 HRP20120479TT HRP20120479T HRP20120479T1 HR P20120479 T1 HRP20120479 T1 HR P20120479T1 HR P20120479T T HRP20120479T T HR P20120479TT HR P20120479 T HRP20120479 T HR P20120479T HR P20120479 T1 HRP20120479 T1 HR P20120479T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- droxidopa
- combination
- combinations
- group
- Prior art date
Links
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 title claims abstract 24
- 229960001104 droxidopa Drugs 0.000 title claims abstract 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims 28
- 150000001875 compounds Chemical class 0.000 claims abstract 42
- 230000002401 inhibitory effect Effects 0.000 claims abstract 21
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims abstract 10
- 102000003914 Cholinesterases Human genes 0.000 claims abstract 8
- 108090000322 Cholinesterases Proteins 0.000 claims abstract 8
- 229940048961 cholinesterase Drugs 0.000 claims abstract 8
- 102000010909 Monoamine Oxidase Human genes 0.000 claims abstract 3
- 108010062431 Monoamine oxidase Proteins 0.000 claims abstract 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims abstract 2
- 206010031127 Orthostatic hypotension Diseases 0.000 claims abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 18
- 229960003337 entacapone Drugs 0.000 claims 12
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 12
- 229960004603 tolcapone Drugs 0.000 claims 12
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 12
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims 9
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims 9
- 229960003530 donepezil Drugs 0.000 claims 9
- 229960002290 pyridostigmine Drugs 0.000 claims 9
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 6
- UPMRZALMHVUCIN-UHFFFAOYSA-N Nitecapone Chemical compound CC(=O)C(C(C)=O)=CC1=CC(O)=C(O)C([N+]([O-])=O)=C1 UPMRZALMHVUCIN-UHFFFAOYSA-N 0.000 claims 4
- 229950008980 nitecapone Drugs 0.000 claims 4
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 claims 3
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 3
- 229960000451 ambenonium Drugs 0.000 claims 3
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 claims 3
- 229960003748 edrophonium Drugs 0.000 claims 3
- 229960003980 galantamine Drugs 0.000 claims 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 3
- 229960001952 metrifonate Drugs 0.000 claims 3
- 229960002362 neostigmine Drugs 0.000 claims 3
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 claims 3
- 229960001697 physostigmine Drugs 0.000 claims 3
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 3
- 229960004136 rivastigmine Drugs 0.000 claims 3
- 229960001685 tacrine Drugs 0.000 claims 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 3
- -1 thiaphyzovenine Chemical compound 0.000 claims 3
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 claims 3
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 claims 2
- ZSTKHSQDNIGFLM-UHFFFAOYSA-N 5-methoxy-N,N-dimethyltryptamine Chemical compound COC1=CC=C2NC=C(CCN(C)C)C2=C1 ZSTKHSQDNIGFLM-UHFFFAOYSA-N 0.000 claims 2
- 229960003057 nialamide Drugs 0.000 claims 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims 1
- MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 claims 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 claims 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims 1
- PBHFNBQPZCRWQP-QUCCMNQESA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 claims 1
- BEWNZPMDJIGBED-UHFFFAOYSA-N benmoxin Chemical compound C=1C=CC=CC=1C(C)NNC(=O)C1=CC=CC=C1 BEWNZPMDJIGBED-UHFFFAOYSA-N 0.000 claims 1
- 229950011271 benmoxin Drugs 0.000 claims 1
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 claims 1
- 229950004068 brofaromine Drugs 0.000 claims 1
- NKJRRVBTMYRXRB-GGAORHGYSA-N cymserine Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)OC1=CC=C(N(C)[C@@H]2[C@@]3(C)CCN2C)C3=C1 NKJRRVBTMYRXRB-GGAORHGYSA-N 0.000 claims 1
- RWZVPVOZTJJMNU-UHFFFAOYSA-N demarcarium Chemical compound C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 RWZVPVOZTJJMNU-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002589 iproclozide Drugs 0.000 claims 1
- GGECDTUJZOXAAR-UHFFFAOYSA-N iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 claims 1
- 229940070023 iproniazide Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004644 moclobemide Drugs 0.000 claims 1
- 229960000964 phenelzine Drugs 0.000 claims 1
- 229960002309 toloxatone Drugs 0.000 claims 1
- 229960003741 tranylcypromine Drugs 0.000 claims 1
- 102100040999 Catechol O-methyltransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Farmaceutski sastav naznačen je time da se sastoji od droksidope u kombinaciji sa jednim ili više dodatnih spojeva odabranih iz grupe koja sadrži inhibirajuće spojeve katekol O metiltransferaze inhibirajuće spojeve kolinesteraze i njihove kombinacije u kojim droksidopa ijedan ili više dodatnih spojeva su pomiješani u omjeru težine od do Patent sadrži još patentnih zahtjeva
Claims (40)
1. Farmaceutski sastav, naznačen je time da se sastoji od droksidope u kombinaciji sa jednim ili više dodatnih spojeva odabranih iz grupe koja sadrži inhibirajuće spojeve katekol-O-metiltransferaze, inhibirajuće spojeve kolinesteraze i njihove kombinacije, u kojim droksidopa ijedan ili više dodatnih spojeva su pomiješani u omjeru težine od 100:1 do 1:2.
2. Farmaceutski sastav, prema zahtjevu 1, naznačen je time da su u njemu inhibirajući spojevi katekol-O-metiltransferaze odabrani iz grupe koja se sastoji od entakapona, tolkapona, nitekapona i njihovih kombinacija.
3. Farmaceutski sastav, prema zahtjevu 1, naznačen je time da su u njemu inhibirajući spojevi kolinesteraze odabrani iz grupe koja se sastoji od piridostigmina, donepezila. rivastigmina. galantamina, takrina, neostigmina, metrifonata, fizostigmina, ambenonij, demarkarija. tiafizovenina, fenzerina, edrofonija, cimserina i njihovih kombinacija.
4. Farmaceutski sastav, prema zahtjevu 1, naznačen time da je u njemu jedan ili više dodatnih spojeva odabrano iz grupe koja se sastoji od entakapona, tolkapona, piridostigmina. donepezila i njihovih kombinacija.
5. Farmaceutski sastav, prema zahtjevu 1, naznačen je time da sadrži droksidopu u kombinacijama sa tolkaponom.
6. Farmaceutski sastav, prema zahtjevu 1, naznačen je time da sadrži droksidopu u kombinacijama sa piridostigminom.
7. Farmaceutski sastav, prema zahtjevu 1, naznačen je time da sadrži droksidopu u kombinacijama s entakaponom.
8. Farmaceutski sastav, prema zahtjevu 1, naznačen je time da sadrži droksidopu u kombinacijama s donepezilom.
9. Farmaceutski sastav, prema zahtjevu 1, naznačen je time da su u njemu droksidopa i jedan ili više dodatnih spojeva pomiješani u omjeru težine od oko 50:1 do oko 2:1.
10. Farmaceutski sastav, naznačen je time da se sastoji od droksidope u kombinaciji sa jednim ili više dodatnih spojeva odabranih iz grupe koja sadrži inhibirajuće spojeve katekol-O-metiltransferaze, inhibirajuće spojeve kolinesteraze i njihove kombinacije, u kojim sastav sadrži 10 mg do 2 g droksidope i 1 mg do 200 mg jednog ili više dodatnih spojeva.
11. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da sadrži 1 mg do 200 mg inhibirajućeg spoja katekol-O-metiltransferaze.
12. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da sadrži 1 mg do 200 mg kolinesteraze inhibirajućeg spoja.
13. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da su u njemu katekol-O- metiltransferaze inhibirajući spojevi odabrani iz grupe koja se sastoji od entakapon, tolkapona, nitekapona i njihovih kombinacija.
14. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da su u njemu inhibirajući spojevi kolinesteraze odabrani iz grupe koja se sastoji od piridostigmina, donepezila, rivastigmina. galantamina, takrina, neostigmina, metrifonata, fizostigmina, ambenonija, demarkarija, tiafizovenina, fenzerina, edrofonija, cimserina i njihovih kombinacija.
15. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da je u njemu jedan ili više dodatnih spojeva odabrani iz grupe koja se sastoji od entakapona, tolkapona, piridostigmina, donepezila i njihovih kombinacija.
16. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da sadrži droksidopu u kombinacijama sa tolkaponom.
17. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da sadrži droksidopu u kombinacijama sa piridostigminom.
18. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da sadrži droksidopu u kombinacijama s entakaponom.
19. Farmaceutski sastav, prema zahtjevu 10, naznačen je time da sadrži droksidopu u kombinacijama s donepezilom.
20. Farmaceutski sastav, naznačen je time da se sastoji od droksidope u kombinaciji sa jednim ili više dodatnih spojeva odabranih iz grupe koja sadrži inhibirajuće spojeve katekol-O-metiltransferaze, inhibirajuće spojeve kolinesteraze i njihove kombinacije, u kojim je kombinacija dana kao pojedinačna jedinica za doziranje.
21. Farmaceutski sastav, prema zahtjevu 20, naznačen je time da su u njemu inhibirajući spojevi katekol-O-metiltransferaze odabrani iz grupe koja se sastoji od entakapona, tolkapona, nitekapona i njihovih kombinacija.
22. Farmaceutski sastav, prema zahtjevu 20, naznačen je time da su u njemu inhibirajući spojevi kolinesteraze odabrani iz grupe koja se sastoji od piridostigmina, donepezila, rivastigmina. galantamina, takrina, neostigmina, metrifonata, fizostigmina, ambenonija, demarkarijuma. tiafizovenina, fenzerina, edrofonija, cimserina i njihovih kombinacija.
23. Farmaceutski sastav, prema zahtjevu 20, naznačen time da je u njemu jedan ili više dodatnih spojeva odabrano iz grupe koja se sastoji od entakapona, tolkapona, piridostigmina, donepezila i njihovih kombinacija.
24. Farmaceutski sastav, prema zahtjevu 20, naznačen je time da sadrži droksidopu u kombinacijama sa tolkaponom.
25. Farmaceutski sastav, prema zahtjevu 20, naznačen je time da sadrži droksidopu u kombinacijama sa piridostigminom.
26. Farmaceutski sastav, prema zahtjevu 20, naznačen je time da sadrži droksidopu u kombinacijama s entakaponom.
27. Farmaceutski sastav, prema zahtjevu 20, naznačen je time da sadrži droksidopu u kombinacijama s donepezilom.
28. Upotreba droksidope u kombinaciji s jednim ili više dodatnih spojeva, naznačena je time da su odabrani iz grupe koja se sastoji od inhibirajućih spojeva katekol-O- metiltransferaze, inhibirajućih spojeva monoamin oksidaze i njihovih kombinacija za proizvodnju lijeka za liječenje ortostatičke hipotenzije.
29. Upotreba, prema zahtjevu 28, naznačena je time da jedan ili više dodatnih spojeva su kombinirani u omjeru težine od 3 00:1 do 3:2.
30. Upotreba, prema zahtjevu 28, naznačena je time da jedan ili više dodatnih spojeva su kombinirani u omjeru težine od 50:1 do 2:1.
31. Upotreba, prema zahtjevu 28, naznačena je time da kombinacija sadrži 10 mg do 2 g droksidope i 1 mg do 200 mg jednog ili više dodatnih spojeva.
32. Upotreba, prema zahtjevu 28, naznačena je time da je u kombinaciji dana pojedinačna jedinica za doziranje.
33. Upotreba, prema bilo kojem zahtjevu od 28 do 31, naznačena je time da se droksidopa i jedan ili više dodatnih spojeva primjenjuju istovremeno.
34. Upotreba, prema bilo kojem zahtjevu od 28 do 31, naznačena je time da se droksidopa i jedan ili više dodatnih spojeva primjenjuju periodično.
35. Upotreba, prema bilo kojem zahtjevu od 28 do 32, naznačena je time da su inhibirajući spojevi katekol-O-metiltransferaze odabrani iz grupe koja se sastoji od entakapona. tolkapona. nitekapona i njihovih kombinacija.
36. Upotreba, prema bilo kojem od zahtjeva od 28 do 32, naznačena je time da su inhibirajući spojevi monoamin oksidaze odabrani iz grupe koja se sastoji od izokarboksazida. moklobemida, fenelzina, tranilcipromina, seiegilina, nialamida, iproniazida, iproklozida, toloksatona, harmala, brofaromina, benmoksina, 5-metoksi-N,N-dimetiltriptamina, 5-metoksi-ametiltriptamina i njihovih kombinacija.
37. Upotreba, prema bilo kojem zahtjevu od 28 do 32, naznačena je time da su jedan ili više dodatnih spojeva odabrani iz grupe koja se sastoji od entakapona, tolkapona, nialmida i njihovih kombinacija.
38. Upotreba, prema bilo kojem zahtjevu od 28 do 32, naznačena je time da jedan ili više dodatnih spojeva je entakapon.
39. Upotreba, prema bilo kojem zahtjevu od 28 do 32, naznačena je time da jedan ili više dodatnih spojeva je tolkapon.
40. Upotreba, prema bilo kojem zahtjevu od 28 do 32, naznačena je time da jedan ili više dodatnih spojeva je nialamid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80603606P | 2006-06-28 | 2006-06-28 | |
| PCT/US2007/072334 WO2008003028A2 (en) | 2006-06-28 | 2007-06-28 | Pharmaceutical compositions comprising droxidopa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120479T1 true HRP20120479T1 (hr) | 2012-07-31 |
Family
ID=38698773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120479TT HRP20120479T1 (hr) | 2006-06-28 | 2012-06-06 | Farmaceutski sastavi sa droksidopom |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080015181A1 (hr) |
| EP (3) | EP1948155B1 (hr) |
| AT (1) | ATE548034T1 (hr) |
| DK (1) | DK1948155T3 (hr) |
| ES (2) | ES2383768T3 (hr) |
| HR (1) | HRP20120479T1 (hr) |
| PL (1) | PL1948155T3 (hr) |
| PT (1) | PT1948155E (hr) |
| WO (1) | WO2008003028A2 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158149B2 (en) | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
| WO2004100929A1 (en) | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
| NZ579368A (en) * | 2007-03-09 | 2012-03-30 | Chelsea Therapeutics Inc | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
| EP2142185B1 (en) * | 2007-03-12 | 2012-08-15 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
| ES2431570T3 (es) | 2007-05-07 | 2013-11-27 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención |
| US8388656B2 (en) * | 2010-02-04 | 2013-03-05 | Ebi, Llc | Interspinous spacer with deployable members and related method |
| JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
| BR112014018851A2 (pt) | 2012-01-31 | 2017-07-04 | Lundbeck Na Ltd | melhoramento da estabilidade postural administrando droxidopa |
| US20130253061A1 (en) | 2012-03-20 | 2013-09-26 | Chelsea Therapeutics, Inc. | Method of droxidopa synthesis |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| GB202008961D0 (en) * | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| KR20230024378A (ko) | 2020-06-12 | 2023-02-20 | 벡클리 싸이테크 리미티드 | 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3920728A (en) | 1973-08-22 | 1975-11-18 | Hoffmann La Roche | Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine |
| JPS5419931A (en) * | 1977-07-11 | 1979-02-15 | Sumitomo Chem Co Ltd | Separation of threo, erythro-3-(3,4-dibenzyloxyphenyl)serines |
| US4319046A (en) * | 1977-07-22 | 1982-03-09 | The Sherwin-Williams Company | Preparation of 1,2 diaminobenzene by high pressure acid hydrolysis of benzemidazolone |
| JPS5629551A (en) | 1979-08-20 | 1981-03-24 | Sumitomo Chem Co Ltd | Preparation of optically active threo-3- 3,4- dihydroxyphenyl serine |
| JPS56104815A (en) | 1980-01-23 | 1981-08-20 | Sumitomo Chem Co Ltd | Remedy for peripheral orthostatic hypotension |
| US4421767A (en) * | 1981-06-01 | 1983-12-20 | Merrell Toraude Et Compagnie | Compounds and methods for treating depression |
| JPS5852219A (ja) * | 1981-09-22 | 1983-03-28 | Sumitomo Chem Co Ltd | パ−キンソン病治療剤 |
| US4480109A (en) * | 1982-01-14 | 1984-10-30 | Sumitomo Chemical Company, Limited | Process for producing threo-3-(3,4-dihydroxyphenyl)serine |
| CA1223602A (en) | 1983-05-25 | 1987-06-30 | Naohito Ohashi | Process for producing 3-(3,4-dihydroxyphenyl) serine |
| JPS6067420A (ja) * | 1983-09-22 | 1985-04-17 | Sumitomo Chem Co Ltd | 精神運動興奮抑制剤 |
| JPS6098995A (ja) | 1983-11-04 | 1985-06-01 | Microbial Chem Res Found | 光学活性３−（３，４−ジヒドロキシフエニル）セリン，およびその誘導体の製造法 |
| JPS6185318A (ja) * | 1984-10-04 | 1986-04-30 | Sumitomo Seiyaku Kk | 利尿薬 |
| JPS62106015A (ja) * | 1985-10-31 | 1987-05-16 | Sumitomo Pharmaceut Co Ltd | 抗痴呆薬 |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| GB8720600D0 (en) * | 1987-09-02 | 1987-10-07 | Saad Al Damluji | Pharmaceutical compositions |
| US5240930A (en) * | 1987-09-02 | 1993-08-31 | National Research Development Corporation | Pharmaceutical compositions for treatment of depression and low blood pressure |
| US5015564A (en) * | 1988-12-23 | 1991-05-14 | Eastman Kodak Company | Stabilizatin of precipitated dispersions of hydrophobic couplers, surfactants and polymers |
| JP2603566B2 (ja) * | 1991-03-27 | 1997-04-23 | 住友製薬株式会社 | 尿失禁治療剤 |
| JP3559572B2 (ja) * | 1993-01-29 | 2004-09-02 | 住友製薬株式会社 | 急性痛および慢性痛用鎮痛剤 |
| JP3764179B2 (ja) * | 1994-07-05 | 2006-04-05 | 克寛 西野 | 運動・意識または言語障害の機能改善剤 |
| DE19619510A1 (de) * | 1995-05-18 | 1996-11-21 | Sumitomo Chemical Co | Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin |
| GB9510481D0 (en) * | 1995-05-24 | 1995-07-19 | Orion Yhtymae Oy | New catechol derivatives |
| US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6746688B1 (en) * | 1996-10-13 | 2004-06-08 | Neuroderm Ltd. | Apparatus for the transdermal treatment of Parkinson's disease |
| JPH115738A (ja) * | 1997-06-15 | 1999-01-12 | Katsuhiro Nishino | 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤 |
| US6033993A (en) * | 1997-09-23 | 2000-03-07 | Olin Microelectronic Chemicals, Inc. | Process for removing residues from a semiconductor substrate |
| US6001607A (en) * | 1998-04-13 | 1999-12-14 | Incyte Pharmaceuticals, Inc. | Human growth-associated methyltransfeases |
| FR2777781B1 (fr) * | 1998-04-24 | 2004-04-09 | Rhone Poulenc Rorer Sa | Associations riluzole et l-dopa pour le traitement de la maladie de parkinson |
| US20020177593A1 (en) * | 1998-09-30 | 2002-11-28 | Yuji Ishihara | Agents and crystals for improving excretory potency of urinary bladder |
| NZ512027A (en) * | 1998-11-10 | 2004-04-30 | Teva Pharma | Dispersible compositions containing L-dopa ethyl ester |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| US6610324B2 (en) * | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
| ATE305307T1 (de) * | 1999-07-01 | 2005-10-15 | Pharmacia & Upjohn Co Llc | Reboxetin zur behandlung von migränekopfschmerzen |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| AU2002246490A1 (en) * | 2000-10-12 | 2002-07-30 | Pharmacia And Upjohn Company | Method of treating parkinson's disease |
| CA2463624A1 (en) * | 2001-10-15 | 2003-04-24 | National Research Council Of Canada | Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| BR0308556A (pt) * | 2002-03-21 | 2005-05-03 | Martin C Hinnz | Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas |
| US7897639B2 (en) * | 2003-10-21 | 2011-03-01 | Colucid Pharmaceuticals, Inc. | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
| EP1737473A4 (en) * | 2004-04-19 | 2009-08-26 | Noven Therapeutics Llc | COMBINATIONS OF LITHIUM AND USES THEREOF |
| US20070004639A1 (en) * | 2005-07-01 | 2007-01-04 | Bodybio, Inc. | Methods and compositions for treating Parkinson's disease |
-
2007
- 2007-06-28 EP EP07784556A patent/EP1948155B1/en active Active
- 2007-06-28 DK DK07784556.8T patent/DK1948155T3/da active
- 2007-06-28 US US11/770,191 patent/US20080015181A1/en not_active Abandoned
- 2007-06-28 EP EP11165690A patent/EP2363123A1/en not_active Withdrawn
- 2007-06-28 WO PCT/US2007/072334 patent/WO2008003028A2/en active Application Filing
- 2007-06-28 PL PL07784556T patent/PL1948155T3/pl unknown
- 2007-06-28 ES ES07784556T patent/ES2383768T3/es active Active
- 2007-06-28 AT AT07784556T patent/ATE548034T1/de active
- 2007-06-28 PT PT07784556T patent/PT1948155E/pt unknown
- 2007-06-28 ES ES11165693T patent/ES2571730T3/es active Active
- 2007-06-28 EP EP11165693.0A patent/EP2363124B1/en active Active
-
2012
- 2012-06-06 HR HRP20120479TT patent/HRP20120479T1/hr unknown
-
2015
- 2015-10-16 US US14/885,158 patent/US20160106694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2383768T3 (es) | 2012-06-26 |
| US20080015181A1 (en) | 2008-01-17 |
| EP2363123A1 (en) | 2011-09-07 |
| US20160106694A1 (en) | 2016-04-21 |
| PL1948155T3 (pl) | 2012-10-31 |
| PT1948155E (pt) | 2012-06-15 |
| DK1948155T3 (da) | 2012-07-02 |
| EP1948155A2 (en) | 2008-07-30 |
| EP2363124A1 (en) | 2011-09-07 |
| EP1948155B1 (en) | 2012-03-07 |
| EP2363124B1 (en) | 2016-02-17 |
| WO2008003028A3 (en) | 2008-03-20 |
| WO2008003028A2 (en) | 2008-01-03 |
| ES2571730T3 (es) | 2016-05-26 |
| ATE548034T1 (de) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120479T1 (hr) | Farmaceutski sastavi sa droksidopom | |
| Griffiths et al. | Pharmacological modulation of the mitochondrial electron transport chain in paclitaxel-induced painful peripheral neuropathy | |
| Blanchet et al. | Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease | |
| Pledgie-Tracy et al. | The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines | |
| BRPI0506977A (pt) | composto de tetrahidrocarbolina como agentes anticáncer | |
| WO2007047327A3 (en) | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency | |
| WO2009128918A8 (en) | Combination therapy using a soluble hyaluronidase and a bisphosphonate | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| CA2442168A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| DK1750716T3 (da) | Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin | |
| WO2007123511A3 (en) | Dosing regimens for the treatment of cancer | |
| WO2008116161A3 (en) | Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states | |
| CA2563058A1 (en) | Supportive treatment of liver disease | |
| WO2008112773A3 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| HRP20120228T1 (hr) | Kladribinski režim za liječenje multiple skleroze | |
| MA56827B2 (fr) | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine | |
| WO2001034614A3 (en) | Compositions and methods for double-targeting virus infections and targeting cancer cells | |
| MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
| Bortscher et al. | Hemin induction of HO-1 protects against LPS-induced septic ileus | |
| MX2009006114A (es) | Composiciones que comprenden carisoprodol y metodos de uso de las mismas. | |
| TW200719903A (en) | Compositions for the treatment of neoplasms | |
| EP2581091B1 (fr) | Utilisation de protoxyde d'azote inhalé pour prévenir des douleurs neuropathiques induites par les sels de platine | |
| RU2015126505A (ru) | Применение и способы лечения заболеваний и патологических состояний печени | |
| Lee et al. | Bupivacaine-induced contraction is attenuated by endothelial nitric oxide release modulated by activation of both stimulatory and inhibitory phosphorylation (Ser1177 and Thr495) of endothelial nitric oxide synthase |